Last reviewed · How we verify
TABELECLEUCEL
At a glance
| Generic name | TABELECLEUCEL |
|---|---|
| Modality | Cell therapy |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2022 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (PHASE2)
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy (PHASE3)
- EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (PHASE1)
- T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (PHASE1)
- EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection (PHASE2)
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (PHASE1)
- EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases (PHASE1,PHASE2)
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TABELECLEUCEL CI brief — competitive landscape report
- TABELECLEUCEL updates RSS · CI watch RSS